A smarter way to deliver drugs into cells

Eos Biosciences has developed the Eosome, a versatile drug delivery platform that maximizes efficacy through efficient intracellular delivery of therapeutic payloads. Eosomes can be adapted for many disease indications and for the delivery of a wide variety of drug modalities. To download the full article, please sign in.

Like Comment
Page of
Go to the profile of Eos Biosciences, Inc

Eos Biosciences, Inc

Eos Biosciences Inc. is a privately-held, Los Angeles-based, Biotargeted Nanomedicines company founded in 2013. The Company has secured an exclusive world-wide license to a novel drug-targeting platform technology developed at Cedars-Sinai Medical Center (Los Angeles). The technology is based on generating self-assembling, non-liposomal, biotargeted nanoparticles (Eosomes) that entrap and encapsulate a chosen therapeutic and specifically deliver it to the interior of the target disease cell by mediating active endosomal escape. Such specific targeting allows for improved efficacy and safety profiles of the therapeutic payload. The Eosomes efficiently entrap and package small molecule therapeutics as well as many forms of oligonulceotide therapeutics including single and double strand DNA oligonucleotides, siRNA, miRNA, mRNA and plasmid DNA. Eos Biosciences has a pipeline of proprietary products for oncology specifically targeting a wide variety of metastatic, drug resistant, solid tumors. Eos anticipates advancing the first proof of principle product into phase 1 clinical study in 2017.

No comments yet.